Pliant Therapeutics (PLRX) CEO resets multiple option grants to $1.33

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Pliant Therapeutics President and CEO Bernard Coulie reported an option repricing affecting several existing stock option grants. On the April 17, 2026 effective date, multiple options covering common stock were surrendered to the issuer and regranted with a new exercise price of $1.33 per share, replacing higher original exercise prices such as $34.65 and $26.50. The board approved this repricing for options granted on or before March 1, 2025, with all other terms unchanged.

The repriced options will revert to their original exercise prices if exercised during an eighteen‑month Retention Period starting April 17, 2026, or upon certain termination or resignation events described in the CEO’s severance plan. Several option expiration dates were also corrected, including updates to January 24, 2029 and March 31, 2030.

Insider Trade Summary

14 transactions reported

Mixed 14 txns

Insider Coulie Bernard

Role President and CEO

Type	Security	Shares	Price	Value
Disposition	Stock Option (Right to Buy)	146,841	$0.00	--
Grant/Award	Stock Option (Right to Buy)	146,841	$0.00	--
Disposition	Stock Option (Right to Buy)	327,262	$0.00	--
Grant/Award	Stock Option (Right to Buy)	327,262	$0.00	--
Disposition	Stock Option (Right to Buy)	250,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	250,000	$0.00	--
Disposition	Stock Option (Right to Buy)	440,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	440,000	$0.00	--
Disposition	Stock Option (Right to Buy)	206,300	$0.00	--
Grant/Award	Stock Option (Right to Buy)	206,300	$0.00	--
Disposition	Stock Option (Right to Buy)	256,300	$0.00	--
Grant/Award	Stock Option (Right to Buy)	256,300	$0.00	--
Disposition	Stock Option (Right to Buy)	325,000	$0.00	--
Grant/Award	Stock Option (Right to Buy)	325,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct)

Footnotes (1)

On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged. The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates. The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029. The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan). The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan). The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030. The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031. The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032. The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033.

Key Figures

Repriced exercise price: $1.33 per share Repriced option grant: 146,841 options Repriced option grant: 327,262 options +4 more

7 metrics

Repriced exercise price $1.33 per share New exercise price for multiple CEO stock option grants effective April 17, 2026

Repriced option grant 146,841 options Stock option covering 146,841 shares repriced from $2.08 to $1.33 exercise price

Repriced option grant 327,262 options Stock option covering 327,262 shares repriced from $6.22 to $1.33 exercise price

Largest repriced block 440,000 options Stock option for 440,000 shares repriced from $11.86 to $1.33 exercise price

High original strike $34.65 per share Original exercise price of a 206,300‑share option before repricing to $1.33

Retention Period length 18 months Maximum duration from April 17, 2026 before repriced options lose reversion feature

Corrected expiration date January 24, 2029 Updated expiration date for one CEO option grant originally misreported

Key Terms

option repricing, Retention Period, Corporate Transaction, Sale Event, +2 more

6 terms

option repricing financial

"the Issuer's board of directors approved an option repricing (the "Repricing")"

Retention Period financial

"The "Retention Period" commenced on the Effective Date and ends on the earliest"

Corporate Transaction financial

"the consummation of a Corporate Transaction (as defined by the 2015 Plan)"

Sale Event financial

"or a Sale Event (as defined by the 2020 Plan)"

severance plan financial

"as defined in the Reporting Person's severance plan"

Equity Incentive Plan financial

"issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Form 4 Insider Transactions: What Each Field Means →

04/17/2026 - 04:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coulie Bernard

(Last)

(First)

(Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.08	04/17/2026		D⁽¹⁾			146,841	⁽²⁾	01/24/2029⁽³⁾	Common Stock	146,841	$0	0	D
Stock Option (Right to Buy)	$1.33⁽⁴⁾⁽⁵⁾	04/17/2026		A⁽¹⁾		146,841		⁽²⁾	01/24/2029⁽³⁾	Common Stock	146,841	$0	146,841	D
Stock Option (Right to Buy)	$6.22	04/17/2026		D⁽¹⁾			327,262	⁽²⁾	03/31/2030⁽⁶⁾	Common Stock	327,262	$0	0	D
Stock Option (Right to Buy)	$1.33⁽⁴⁾⁽⁵⁾	04/17/2026		A⁽¹⁾		327,262		⁽²⁾	03/31/2030⁽⁶⁾	Common Stock	327,262	$0	327,262	D
Stock Option (Right to Buy)	$26.5	04/17/2026		D⁽¹⁾			250,000	⁽²⁾	01/23/2031⁽⁷⁾	Common Stock	250,000	$0	0	D
Stock Option (Right to Buy)	$1.33⁽⁴⁾⁽⁵⁾	04/17/2026		A⁽¹⁾		250,000		⁽²⁾	01/23/2031⁽⁷⁾	Common Stock	250,000	$0	250,000	D
Stock Option (Right to Buy)	$11.86	04/17/2026		D⁽¹⁾			440,000	⁽²⁾	01/26/2032⁽⁸⁾	Common Stock	440,000	$0	0	D
Stock Option (Right to Buy)	$1.33⁽⁴⁾⁽⁵⁾	04/17/2026		A⁽¹⁾		440,000		⁽²⁾	01/26/2032⁽⁸⁾	Common Stock	440,000	$0	440,000	D
Stock Option (Right to Buy)	$34.65	04/17/2026		D⁽¹⁾			206,300	⁽²⁾	01/25/2033⁽⁹⁾	Common Stock	206,300	$0	0	D
Stock Option (Right to Buy)	$1.33⁽⁴⁾⁽⁵⁾	04/17/2026		A⁽¹⁾		206,300		⁽²⁾	01/25/2033⁽⁹⁾	Common Stock	206,300	$0	206,300	D
Stock Option (Right to Buy)	$17.44	04/17/2026		D⁽¹⁾			256,300	⁽²⁾	01/23/2034	Common Stock	256,300	$0	0	D
Stock Option (Right to Buy)	$1.33⁽⁴⁾⁽⁵⁾	04/17/2026		A⁽¹⁾		256,300		⁽²⁾	01/23/2034	Common Stock	256,300	$0	256,300	D
Stock Option (Right to Buy)	$11.14	04/17/2026		D⁽¹⁾			325,000	⁽²⁾	01/23/2035	Common Stock	325,000	$0	0	D
Stock Option (Right to Buy)	$1.33⁽⁴⁾⁽⁵⁾	04/17/2026		A⁽¹⁾		325,000		⁽²⁾	01/23/2035	Common Stock	325,000	$0	325,000	D

Explanation of Responses:

1. On April 15, 2026, the Issuer's board of directors approved an option repricing (the "Repricing"), effective April 17, 2026 (the "Effective Date"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged.

2. The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the "2015 Plan"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the "2020 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates.

3. The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029.

4. The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan).

5. The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan).

6. The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030.

7. The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031.

8. The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032.

9. The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Pliant Therapeutics (PLRX) CEO Bernard Coulie report on this Form 4?

He reported an option repricing where several existing stock option grants were surrendered and reissued at a new exercise price of $1.33 per share, with all other terms unchanged and subject to previously disclosed vesting schedules under company equity plans.

Which stock options for PLRX’s CEO were repriced in this filing?

Multiple option grants covering common stock were repriced, including awards for 146,841, 327,262, 250,000, 440,000, 206,300, 256,300 and 325,000 shares. Each was disposed of at its original higher exercise price and regranted at $1.33 per share on April 17, 2026.

What is the new exercise price for Bernard Coulie’s repriced PLRX stock options?

Each repriced option now has an exercise price of $1.33 per share. These options replaced prior grants that carried higher exercise prices, including $34.65, $26.50, $17.44 and $11.14 per share, while maintaining the same share counts and general terms.

When did the Pliant Therapeutics board approve the CEO option repricing?

The board approved the option repricing on April 15, 2026, with an effective date of April 17, 2026. The action applied to stock options granted on or before March 1, 2025 for current employees, including the CEO, with other option terms remaining unchanged.

What is the Retention Period for the repriced PLRX stock options?

The Retention Period began on April 17, 2026 and lasts until the earliest of eighteen months later, completion of a defined Corporate Transaction or Sale Event, certain qualifying terminations, or resignation for good reason, as specified in the CEO’s severance plan documents.

When do Bernard Coulie’s corrected PLRX option grants expire?

Several expiration dates were corrected, including updates to January 24, 2029, March 31, 2030, January 23, 2031, January 26, 2032 and January 25, 2033. These corrections align the option records with the intended original expiration dates previously disclosed.